News | May 26, 2025
Biocon Biologics receives MHRA, UK approval for biosimilar YESINTEK
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
The biosimilar Ustekinumab has been developed and manufactured by the company
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list
Yesafili, received marketing authorization approval from the European Commission for the European Union
The RCSed's Court of Regents comprises a group of distinguished and accomplished individuals in their field
Subscribe To Our Newsletter & Stay Updated
